Maze Therapeutics Advances Kidney Disease Treatment with MZE829 Study

Maze Therapeutics, Inc. ((MAZE)) announced an update on their ongoing clinical study.

Study Overview: Maze Therapeutics, Inc. is conducting a Phase 2 study titled An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype. The study aims to assess the safety and effectiveness of MZE829 in reducing albuminuria in patients with APOL1 kidney disease, a condition characterized by proteinuria and chronic kidney issues. This study is significant as it targets a genetic risk factor prevalent in certain populations, potentially offering a new treatment avenue.

Intervention/Treatment: The study tests MZE829, an experimental drug administered orally in capsule form. It is designed to treat chronic kidney disease in patients with and without concurrent diabetes, focusing on those with the APOL1 high-risk genotype.

Study Design: This interventional study employs a single-group model without masking, meaning all participants receive the treatment, and there is no placebo group. The primary purpose is treatment-focused, aiming to evaluate the drug’s impact on kidney disease symptoms.

Study Timeline: The study began on February 7, 2025, with the latest update submitted on August 26, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates on its findings.

Market Implications: The progress of this study could significantly influence Maze Therapeutics’ stock performance, as positive results may enhance investor confidence and market position. Given the targeted nature of the treatment, it could also impact the broader pharmaceutical industry by setting a precedent for genetic-based therapies in kidney disease.

The study is currently recruiting, with further details available on the ClinicalTrials portal.